Peer Review History
| Original SubmissionFebruary 23, 2021 |
|---|
|
PONE-D-21-06131 Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida PLOS ONE Dear Dr. Ricotta, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Both reviewers found your study to be a potentially important contribution to the epidemiology of NTM infections in CF patients based on geographic location. If you choose to submit a revised manuscript, Reivew 2 has a number of comments all of which need to be addressed in your response, along with revision of the manuiscript. Please submit your revised manuscript by May 17, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Thomas Byrd Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. Additional Editor Comments: Both reviewers found your manuscript interesting and a potentially important contribution to the role that geographic location plays in the incidence of NTM lung infections in CF patients. Reivewer 2 raises a number of questions that need to be addressed. If you choose to submit a revised version of your manuscript, please respond to the issues raised by Reviewer 2 and modify the manuscript accordingly. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: An important contribution toward understanding the environmental characteristics that are determinants of environmental mycobacterial geographical distribution. I read the article closely, but could find no instances where I thought changes or additions/deletions were needed. Reviewer #2: Review: Foote et al. Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida Manuscript (MS) in review. Interesting and much needed analysis of environmental risk factors for NTM sputum culture positivity. The use of CF patients is a novel and useful approach to identifying those with substantial exposure to NTM. The use of cluster analysis with environmental analysis at the zip code level is a specific and granular approach to identifying potentially important exposures. General comment. This reader had to reread the manuscript multiple times to understand the role of the SE cluster of NTM cases. Were they modelled separately? It does not appear so, the model encompasses the state. I have come to the conclusion that you called them out because you identify them as a cluster and that is all. This is confusing. Maybe there should be less emphasis on this discovery (no inclusion in Figure 2) or somehow otherwise alert the reader that this was an incidental finding. Did you run a cluster analysis on controls? Maybe looking at case and control clusters is another environmental analysis report (suggestion). But in this report, the cluster is a distraction as currently presented. Methods Q- How was zipcode assigned to patient and control? Did you use residential or hospital zipcode or something else? Was the same method used for both patient and control? Q- You analyze sputum positive CF patients (cases) and compare to controls: What is the rate of false negatives among sputum samples for NTM? Did you evaluate later cultures of controls to see if they became cases later during your six year study period? Q-Line 64- you analyzed weather, soil or water mineral concentrations. I did not see the resulting values for these environmental exposures (maybe in a supplement)? Nor do I see a data source for water minerals in Table 1, although soil is listed. Q-How were zip code and census polygons (income, metropolitan centers) reconciled? The reader needs more information about the temporal and spatial variability of covariates to be comfortable with the presence of environmental exposures included in the final model. Because variables such as temperature, precipitation, and evapotranspiration (“weather”) vary greatly month to month, year to year. Sea surface temperatures influence air temperature and precipitation both influence evapotranspiration. Early in your study period, there were anomalous lows, then anomalous highs, then lows again, ending in anomalous highs in 2017 in sea surface temperatures. See: https://twitter.com/MichaelRLowry/status/1249061412896464896/photo/1 (Questions to authors in bold text) This reader is concerned that there is a lack of information about this variability and how “weather” data are related to NTM culture positivity. What is the typical lag between NTM colonization and detection vs sputum sampling? How often are CF patients cultured? Please cite sources. This reader is seeing that analyses were conducted over a six year period (2011-2017). All subjects appear to be lumped into that time period. Mean “weather” variables are defined by year. What is the distribution of NTM culture positivity by month? Please include table. How is weather associated with sputum positivity over time, given potential lags? Was there enough power to perform a temporal analysis between weather and sputum positivity? In short, there is a major mismatch between exposure and outcome. If you wish to include exposure variables that can change so much year to year, as I reader I expect to see time in the model. It is Florida. What about outlier precipitation years due to hurricanes? Effect on sputum positivity? I also expect to see the outcome analyzed by time. But NTM is considered a chronic condition. How do you reconcile this analysis of highly temporally variable “weather” with an outcome (sputum positivity) with no granularity or knowledge of time? Soil is the also problematic. In the absence of additional information in the MS, these are the issues. 1-The reference for soil mineral data: https://pubs.usgs.gov/ds/801/ leads one to a summary report: “U.S. Department of the Interior, U.S. Geological Survey, Data Series 801, Geochemical and Mineralogical Data for Soils of the Conterminous United States” (“Data for Soils”). The report describes sampling methods which include a single point sample collection from “target sites that represented a density of approximately 1 site per 1,600 km2”. Spatial variability of soil minerals is a large concern for this report. Lines 70-72 state ” Where necessary, ordinary kriging was performed to estimate the broader spatial distribution over Florida from the original sampling sites or weather stations. “ This statement comes after “weather” variables were discussed. Is this kriging approach also true for point estimates of minerals in soil by zipcode? Please include citations for why a soil mineral analysis of this type -using kriging among spatial points 1,600 km2 apart, sampled once near the time of the study period, represents the exposure of people living among the points during the study period. When one looks at variability in soil characteristics, this reader was surprised by the extreme temporal and spatial variability in concentrations of minerals. Let’s examine the two that made it to the final model, sodium and manganese. Sodium: the exposure analysis using grid spacing for sodium samples of 1 site per 1,600 km2 appears to be too coarse to estimate your subjects exposures at the zipcode level. See: Trangmar et al. Application of Geostatistics to Spatial Studies of Soil Properties. Advances in Agronomy 1986. https://doi.org/10.1016/S0065-2113(08)60673-2 Manganese: in a study of agricultural fields, manganese concentrations differed among months of the year and over the extent of the field. Areas with higher concentrations did not keep rank order of concentrations over the year. See: Hoskinson, et al. Temporal Changes in the Spatial Variability of Soil Nutrients. INEEL/CON-99-00290. 1999. https://www.osti.gov/servlets/purl/9823-CNgTWm/webviewable/ It appears that soil minerals are variable spatially and temporally due to multiple factors such as land use, vegetative cover, soil microbial communities, and precipitation. Therefore, I fear that your assignment of soil mineral exposure was too simplistic. Please prove me wrong, because we need to better understand environmental risk factors for NTM colonization. Note- attachment preserves figure and bold text features of review. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida PONE-D-21-06131R1 Dear Dr. Ricotta, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Thomas Byrd Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-06131R1 Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida Dear Dr. Ricotta: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Thomas Byrd Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .